Regulatory requirements stipulate that the production of any agents intended for use in human clinical trials must be performed under current Good Manufacturing Practices (cGMP). 1 Retroviral vector ...

Despite the undeniable ability of viral vectors to deliver genetic payloads, and despite the incredible promise of this approach to treat a vast variety of diseases—including metabolic, cardiovascular ...

Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence ...